One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2019-127835
Copy DOI Journal: Blood |  Publication Date: Nov 13, 2019 |
 Citations: 2 |
Affiliation: The University of Texas MD Anderson Cancer Center, The Maria Sklodowska-Curie National Research Institute of Oncology, Postgraduate School of Molecular Medicine, Instytut Hematologii i Transfuzjologi, Northside Hospital, Sarah Cannon, Tennessee Oncology, Cleveland Clinic, Lund University, Washington University in St. LouisSEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
